



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**REVOCATION OF PRIOR POWERS OF ATTORNEY AND APPOINTMENT OF
NEW POWER OF ATTORNEY OR AUTHORIZATION OF AGENTS**

Commissioner for Patents
Alexandria, VA 22313

Sir:

Alexion Pharmaceuticals, Inc. hereby revokes, as appropriate, all previous powers of attorney and authorizations of agent previously granted for the following U.S. patent applications:

Application Number	Filing Date	Docket Number
09/528225	03/21/2000	ALXN-P01-021
11/143947	06/03/2005	ALXN-P02-021
11/143943	06/03/2005	ALXN-P03-021
11/143966	06/03/2005	ALXN-P04-021
11/029017	01/05/2005	ALXN-P02-020
11/097812	04/01/2005	ALEX-P02-100
60/783070	03/15/2006	ALXN-P63-114
60/668049	04/04/2005	ALXN-P60-122

The following attorneys or agents of the Fish & Neave IP Group of Ropes & Gray LLP, and all other attorneys or agents affiliated with Customer No.:

28120


are hereby appointed to prosecute applications and transact all business in the United States Patent and Trademark Office for the above applications.

Please change the correspondence address for the above-identified applications to:

Fish & Neave IP Group of
Ropes & Gray LLP
One International Place
Boston, MA 02110

The undersigned, whose title is supplied below, is empowered to sign this
Revocation and New Power of Attorney on behalf of the Assignee.

Respectfully submitted,



Officer

09/07/06

Date

Stephen P. Squinto, Ph.D.

Print or Type Name of Person Signing

Executive Vice President and Head of Research

Title



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Alexion Pharmaceuticals, Inc., a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in the patent applications and patents identified on the attached Schedule A; or
2. ☐ an assignee of less than the entire right, title and interest in the patent applications and patents identified.

The extent (by percentage) of its ownership interest is 1 %

- A. ☒ An assignment from the inventor(s) of the patent applications/patents identified on the attached Schedule A. The assignment was recorded in the United States Patent and Trademark Office at Reel (s) and Frame(s) indicated in Attachment A, or a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

[Signature]
Signature

9/7/06
Date

Stephen P. Squinto, Ph.D.
Printed or Typed Name

203-272-2596
Telephone Number

Executive Vice President & Head of Research
Title

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9/27/06

Signature: [Signature] (Anne Blundell)



ATTACHMENT A

Attorney Docket No.:	ALXN-P01-021		
Applicants:	Wang et al.		
Application No.:	09/528225		
Filed:	March 21, 2000		
Title:	Chimeric Proteins For Diagnosis and Treatment of Diabetes		
Assignee:	Alexion Pharmaceuticals, Inc.		
Recordation Date:	11/14/2000	Reel: 011257	Frame(s): 0138-0141
Attorney Docket No.:	ALXN-P02-021		
Applicants:	Wang et al		
Application No.:	11/143947		
Filed:	June 3, 2005		
Title:	CHIMERIC PROTEINS FOR DIAGNOSIS AND TREATMENT OF DIABETES		
Assignee:	Alexion Pharmaceuticals, Inc.		
Recordation Date:	1/10/2006	Reel: 017444	Frame(s): 0168-0174
Attorney Docket No.:	ALXN-P03-021		
Applicants:	Wang et al		
Application No.:	11/143943		
Filed:	June 3, 2005		
Title:	CHIMERIC PROTEINS FOR DIAGNOSIS AND TREATMENT OF DIABETES		
Assignee:	Alexion Pharmaceuticals, Inc.		
Recordation Date:	1/10/06	Reel: 017444	Frame(s): 0180-0186
Attorney Docket No.:	ALXN-P04-021		
Applicants:	Wang et al.		
Application No.:	11/143966		
Filed:	June 3, 2005		
Title:	CHIMERIC PROTEINS FOR DIAGNOSIS AND TREATMENT OF DIABETES		
Assignee:	Alexion Pharmaceuticals, Inc.		
Recordation Date:	1/10/06	Reel: 017444	Frame(s): 0215-0221

Attorney Docket No.:	ALXN-P02-020		
Applicants:	Wang et al.		
Application No.:	11/029017		
Filed:	January 5, 2005		
Title:	METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASE		
Assignee:	Alexion Pharmaceuticals, Inc.		
Recordation Date:	6/06/05	Reel: 016665	Frame(s): 0750-0752
Attorney Docket No.:	ALEX-P02-100		
Applicants:	Bowdish et al.		
Application No.:	11/097812		
Filed:	April 1, 2005		
Title:	METHOD OF TREATING AUTOIMMUNE DISEASE BY INDUCING ANTIGEN PRESENTATION BY TOLERANCE INDUCING ANTIGEN PRESENTING CELLS		
Assignee:	Alexion Pharmaceuticals, Inc.		
Recordation Date:	8/12/2005	Reel: 016877	Frame(s): 0410-0414
Attorney Docket No.:	ALXN-P63-114		
dApplicants:	Bell et al.		
Application No.:	60/783,070		
Filed:	March 15, 2006		
Title:	QUALITY OF LIFE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS TREATED WITH AN INHIBITOR OF COMPLEMENT		
Assignee:	Alexion Pharmaceuticals, Inc.		
Recordation Date:	6/22/06	Reel: 017837	Frame(s): 0828-0831
Attorney Docket No.:	ALXN-P60-122		
Applicants:	Rother		
Application No.:	60/668049		
Filed:	April 4, 2005		
Title:	TREATMENT OF DISEASE CAUSED BY EXCESS FREE HEMOGLOBIN		
Assignee:	[NOT YET ASSIGNED]		
Recordation Date:		Reel:	Frame(s):